Editorial: Intravenous Proton Pump Inhibitors for Bleeding Peptic Ulcer: What is the Most Cost-Effective Approach?
Am J Gastroenterol
; 111(10): 1399-1401, 2016 10.
Article
en En
| MEDLINE
| ID: mdl-27694876
ABSTRACT
During their lifetime, about 10% of the population will develop a peptic ulcer. Despite major advancements in the approach to peptic ulcer bleeding over the last 10-20 years including newer endoscopic hemostatic techniques and the advent of proton pump inhibitors (PPIs), upper gastrointestinal bleeding due to peptic ulcers results in substantial morbidity, mortality, and cost. Both oral and intravenous PPIs have proven to be effective in preventing recurrent bleeding from peptic ulcers. However, the dosing and administration of PPIs have been a source of ongoing debate, specifically in relation to cost. In this issue of the Journal, Lu et al. perform cost analysis demonstrating that costs from bleeding peptic ulcers are influenced more by efficient triage and discharge of patients than the nuances of variations in administration of intravenous PPI's.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Úlcera Péptica
/
Inhibidores de la Bomba de Protones
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
Idioma:
En
Revista:
Am J Gastroenterol
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos